Dec 3, 2025 06:45AM

Nov 25, 2024 08:41AM

Nov 25, 2024 07:32AM

Nov 18, 2024 08:32AM

Nov 18, 2024 08:30AM

Nov 7, 2024 07:56AM

Nov 7, 2024 07:55AM Cassava Sciences Reports Q3 2024 Financial and Operating Results

Oct 8, 2024 08:15AM

Oct 2, 2024 07:41AM

Sep 27, 2024 06:02AM

Sep 26, 2024 06:15PM

Aug 8, 2024 08:00AM

Jul 30, 2024 08:15AM

Jul 30, 2024 08:15AM Cassava Sciences Announces Expansion of Open-Label Extension Trials

Jul 17, 2024 08:10AM

Jul 17, 2024 08:00AM

Apr 5, 2024 06:00AM

Mar 28, 2024 10:15AM

Mar 25, 2024 09:00PM

Mar 21, 2024 09:00PM

Mar 19, 2024 10:45AM ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Mar 17, 2024 09:00PM

Mar 14, 2024 12:00PM

Mar 12, 2024 09:00PM

Mar 8, 2024 11:30PM

Mar 7, 2024 10:15AM

Mar 4, 2024 09:00PM

Mar 1, 2024 10:15AM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Feb 29, 2024 09:00PM

Feb 28, 2024 09:15AM

Feb 28, 2024 09:14AM

Feb 25, 2024 09:00PM

Feb 23, 2024 11:30AM

Feb 21, 2024 09:00PM

Feb 17, 2024 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Feb 13, 2024 09:00PM

Feb 9, 2024 09:00PM

Feb 8, 2024 11:02AM

Feb 5, 2024 09:00PM

Nov 6, 2023 09:15AM

Oct 2, 2023 09:05AM

Oct 2, 2023 09:00AM Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

Sep 18, 2023 09:15AM

Sep 18, 2023 09:15AM

Sep 11, 2023 09:10AM

Sep 11, 2023 09:10AM

Aug 3, 2023 09:09AM

Aug 3, 2023 09:07AM

Jul 5, 2023 09:15AM Cassava Sciences (SAVA) Announces Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease

Jul 5, 2023 09:15AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All